H. Sung et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021)

Article  PubMed  Google Scholar 

F. Bray et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)

Article  PubMed  Google Scholar 

A. Vogel et al., Hepatocellular carcinoma. Lancet. 400(10360), 1345–1362 (2022)

Article  CAS  PubMed  Google Scholar 

M. Zhou et al., Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 394(10204), 1145–1158 (2019)

Article  PubMed  PubMed Central  Google Scholar 

J.D. Gordan et al., Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J. Clin. Oncol. 38(36), 4317–4345 (2020)

Article  CAS  PubMed  Google Scholar 

A. Vogel et al., Hepatocellular carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4), iv238–iv255 (2018)

Article  CAS  PubMed  Google Scholar 

D.Y. Xie et al., 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg. Nutr. 9(4), 452–463 (2020)

Article  PubMed  PubMed Central  Google Scholar 

P. Sidaway, FOLFOX-HAIC active in large HCC. Nat. Rev. Clin. Oncol. 19(1), 5 (2022)

Article  PubMed  Google Scholar 

J.M. Sharib et al., Hepatic artery infusion pumps: a Surgical Toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann. Surg. 276(6), 943–956 (2022)

Article  PubMed  Google Scholar 

N. Lyu et al., Arterial chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J. Clin. Oncol. 40(5), 468–480 (2022)

Article  PubMed  Google Scholar 

N. Lyu et al., Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 69(1), 60–69 (2018)

Article  PubMed  Google Scholar 

Q.J. Li et al., Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for large Hepatocellular Carcinoma: a Randomized Phase III Trial. J. Clin. Oncol. 40(2), 150–160 (2022)

Article  CAS  PubMed  Google Scholar 

M. He et al., Sorafenib Plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: a Randomized Clinical Trial. JAMA Oncol. 5(7), 953–960 (2019)

Article  PubMed  PubMed Central  Google Scholar 

Y. Zhao et al., Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim. et Biophys. acta Reviews cancer. 1874(1), 188391 (2020)

Article  CAS  Google Scholar 

G.L. Su et al., AGA Clinical Practice Guideline on systemic therapy for Hepatocellular Carcinoma. Gastroenterology. 162(3), 920–934 (2022)

Article  PubMed  Google Scholar 

M. Friedlander et al., Pamiparib in combination with tislelizumab in patients with advanced solid tumors: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 20(9), 1306–1315 (2019)

Article  CAS  PubMed  Google Scholar 

Z. Ren et al., Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer 12(1), 72–84 (2022)

S. Qin et al., RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 15(16), 1811–1822 (2019)

Article  CAS  PubMed  Google Scholar 

M.K. He et al., Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther. Adv. Med. Oncol. 13, 17588359211002720 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Fu et al., Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J. Gastroenterol. 58(4), 413–424 (2023)

Article  CAS  PubMed  Google Scholar 

Z. Lai et al., Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur. J. Cancer. 174, 68–77 (2022)

Article  CAS  PubMed  Google Scholar 

J. Zhou et al., Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 9(6), 682–720 (2020)

W.M. Liu et al., Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer. 102(1), 115–123 (2010)

Article  CAS  PubMed  Google Scholar 

J.M. Llovet, R. Lencioni, mRECIST for HCC: performance and novel refinements. J. Hepatol. 72(2), 288–306 (2020)

Article  PubMed  Google Scholar 

E.A. Eisenhauer et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228–247 (2009)

Article  CAS  PubMed  Google Scholar 

R.S. Finn et al., Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382(20), 1894–1905 (2020)

Article  CAS  PubMed  Google Scholar 

M. Kudo et al., Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391(10126), 1163–1173 (2018)

Article  CAS  PubMed  Google Scholar 

J.M. Llovet et al., Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359(4), 378–390 (2008)

Article  CAS  PubMed  Google Scholar 

Y. Xin et al., Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front. Immunol. 13, 929141 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Yuan et al., TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int. J. Surg. 109(5), 1222–1230 (2023)

Article  PubMed  PubMed Central  Google Scholar 

Y. Kato et al., Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8 + T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 14(2), e0212513 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

K. Shigeta et al., Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 Blockade promotes vascular normalization and enhances Antitumor immune responses in hepatocellular carcinoma. Hepatology. 71(4), 1247–1261 (2020)

Article  CAS  PubMed  Google Scholar 

E.V. Malofeeva et al., Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 72(24), 6457–6467 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Chen et al., Hepatic arterial infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or without transhepatic arterial embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and high Tumor Burden: a Multicenter Retrospective Study. J. Hepatocell Carcinoma. 10, 1209–1222 (2023)